Cargando…

Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?

Data from 1661 consecutive subjects with chronic-phase chronic myeloid leukemia (CML) receiving initial imatinib (n = 1379) or a 2(nd)-generation tyrosine-kinase inhibitor (2G-TKI; n = 282) were interrogated to determine whether the Sokal or European Treatment and Outcome Study for CML (EUTOS) long-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiao-Shuai, Gale, Robert Peter, Huang, Xiao-Jun, Jiang, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807391/ https://www.ncbi.nlm.nih.gov/pubmed/34413457 http://dx.doi.org/10.1038/s41375-021-01387-y

Ejemplares similares

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
por: Pfirrmann, Markus, et al.
Publicado: (2020)

Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
por: Xia, Leiming, et al.
Publicado: (2015)

Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India
por: Kuntegowdanahalli, Lakshmaiah Chinnagiriyappa, et al.
Publicado: (2016)

Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
por: Millot, Frédéric, et al.
Publicado: (2017)

Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study
por: Yang, Xiawan, et al.
Publicado: (2020)

Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
por: Chhikara, Sunita, et al.
Publicado: (2018)

Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients
por: Zaidi, Uzma, et al.
Publicado: (2019)

The Sokal Hoax: the sham that shook the Academy
por: Lingua Franca. USA
Publicado: (2000)

The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort
por: Sato, Eriko, et al.
Publicado: (2020)

Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
por: Yu, Lu, et al.
Publicado: (2019)

Evaluation in ELT
por: Weir, Cyril J.
Publicado: (1994)

Cophenetic metrics for phylogenetic trees, after Sokal and Rohlf
por: Cardona, Gabriel, et al.
Publicado: (2013)

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
por: Schäfer, Vivien, et al.
Publicado: (2021)

Distance learning in ELT /
Publicado: (1994)

Reflective practice in ELT /
por: Farrell, Thomas S. C. (Thomas Sylvester Charles)
Publicado: (2019)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

The ELT curriculum : design, innovation, and management /
por: White, Ronald V.
Publicado: (1988)

How to use the Internet in ELT /
por: Teeler, Dede
Publicado: (2000)

Cooperative learning strategies for elt /
por: Luna Martínez, Wendy
Publicado: (2001)

Application of constructivist approaches in ELT : /
por: Vera Vargas, Ivette
Publicado: (2015)

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
por: Christiansson, Lisa, et al.
Publicado: (2013)

Materials and methods in ELT : a teacher's guide /
por: McDonough, Jo
Publicado: (1993)

ELT textbooks and materials : problems in evaluation and development /
Publicado: (1987)

Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy
por: Nodzon, Lisa, et al.
Publicado: (2022)

Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity
por: Janssen, Lando, et al.
Publicado: (2020)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

ELT: new horizons in theory and application
por: Haase, Christoph, et al.
Publicado: (2015)

Workshop “Science with the VLT in the ELT Era”
por: Moorwood, Alan
Publicado: (2008)

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
por: Fernandez, Solène, et al.
Publicado: (2019)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lm3ig0ppgalb0edchdempncmtn